Pfizer initiates Phase 1 study of novel oral antiviral therapeutic agent against SARS-CoV-2

Pfizer
Business & Industry News Channel
Pfizer
Sanofi
AstraZeneca
Earlier today, the MHRA announced their review of the small number of thromboembolic events in over 11 million people who received COVID-19 Vaccine AstraZeneca in the UK.
WHO
AstraZeneca
Eli Lilly and Company
Novartis